Cancer Research Cell Death Mechanisms and Cancer Therapy  Protein Translation and Cancer
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Cancer Research Clinical Cancer Research
Cancer Epidemiology Biomarkers & Prevention Molecular Cancer Therapeutics
Molecular Cancer Research Cancer Prevention Research
Cancer Prevention Journals Portal Cancer Reviews Online
Annual Meeting Education Book Meeting Abstracts Online

This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow reprints & permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by De Larco, J. E.
Right arrow Articles by Furcht, L. T.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by De Larco, J. E.
Right arrow Articles by Furcht, L. T.
[Cancer Research 61, 2857-2861, April 1, 2001]
© 2001 American Association for Cancer Research


Advances in Brief

Progression and Enhancement of Metastatic Potential after Exposure of Tumor Cells to Chemotherapeutic Agents1

Joseph E. De Larco2, Beverly R. K. Wuertz, J. Carlos Manivel and Leo T. Furcht

Department of Laboratory Medicine and Pathology, University of Minnesota, Minneapolis, Minnesota 55455

Data presented in this report indicate short-term in vitro treatment of nonmetastatic MCF-7 breast carcinoma cells with the chemotherapeutic agents-, Adriamycin and/or 5-fluoro-2'-deoxyuridine (FUdR), induced changes in the expressed phenotype. Cells treated sequentially with Adriamycin and FUdR expressed a metastatic phenotype. The results also show short-term exposure of MCF-7 cells to either Adriamycin or FUdR rapidly increases, in a dose-dependent manner, the release of the angiogenic cytokine, interleukin-8(IL-8), which is released at consistently higher levels in metastatic cell lines. Cell populations surviving a single treatment with either one or both of these chemotherapeutic agents continue to stably release IL-8. Survivors of sequential treatment with Adriamycin and FUdR (MCF-7 A/F) release the most IL-8 and express the greatest phenotypic variance from the parental, MCF-7 cells. Parental MCF-7 cells and MCF-7 A/F cells both form primary tumors when used in an orthotopic tumor model; however, the MCF-7 A/F tumors have a more rapid initial growth phase in situ and give rise to spontaneous lung metastases within 10 weeks. A cell line that is established from lung metastases releases more IL-8, has a higher cloning efficiency, and forms looser colonies in monolayer than do their parental cells. These experiments indicate the in vitro exposure of tumor cells to chemotherapeutic agents either selects more aggressive cells or enhances the metastatic potential of the surviving cells.




This article has been cited by other articles:


Home page
J. Pharmacol. Exp. Ther.Home page
C. Wilson, C. Purcell, A. Seaton, O. Oladipo, P. J. Maxwell, J. M. O'Sullivan, R. H. Wilson, P. G. Johnston, and D. J. J. Waugh
Chemotherapy-Induced CXC-Chemokine/CXC-Chemokine Receptor Signaling in Metastatic Prostate Cancer Cells Confers Resistance to Oxaliplatin through Potentiation of Nuclear Factor-{kappa}B Transcription and Evasion of Apoptosis
J. Pharmacol. Exp. Ther., December 1, 2008; 327(3): 746 - 759.
[Abstract] [Full Text] [PDF]


Home page
Clin. Cancer Res.Home page
D. J.J. Waugh and C. Wilson
The Interleukin-8 Pathway in Cancer
Clin. Cancer Res., November 1, 2008; 14(21): 6735 - 6741.
[Abstract] [Full Text] [PDF]


Home page
Endocr Relat CancerHome page
I. Bieche, C. Chavey, C. Andrieu, M. Busson, S. Vacher, L. Le Corre, J.-M. Guinebretiere, S. Burlinchon, R. Lidereau, and G. Lazennec
CXC chemokines located in the 4q21 region are up-regulated in breast cancer
Endocr. Relat. Cancer, December 1, 2007; 14(4): 1039 - 1052.
[Abstract] [Full Text] [PDF]


Home page
Molecular Cancer TherapeuticsHome page
C. J. Sweeney, S. Mehrotra, M. R. Sadaria, S. Kumar, N. H. Shortle, Y. Roman, C. Sheridan, R. A. Campbell, D. J. Murry, S. Badve, et al.
The sesquiterpene lactone parthenolide in combination with docetaxel reduces metastasis and improves survival in a xenograft model of breast cancer
Mol. Cancer Ther., June 1, 2005; 4(6): 1004 - 1012.
[Abstract] [Full Text] [PDF]


Home page
Molecular Cancer TherapeuticsHome page
W.-C. Yen and W. W. Lamph
The selective retinoid X receptor agonist bexarotene (LGD1069, Targretin) prevents and overcomes multidrug resistance in advanced breast carcinoma
Mol. Cancer Ther., May 1, 2005; 4(5): 824 - 834.
[Abstract] [Full Text] [PDF]


Home page
Clin. Cancer Res.Home page
J. E. De Larco, B. R. K. Wuertz, and L. T. Furcht
The Potential Role of Neutrophils in Promoting the Metastatic Phenotype of Tumors Releasing Interleukin-8
Clin. Cancer Res., August 1, 2004; 10(15): 4895 - 4900.
[Abstract] [Full Text] [PDF]


Home page
Proc. Natl. Acad. Sci. USAHome page
J. E. De Larco, B. R. K. Wuertz, D. Yee, B. L. Rickert, and L. T. Furcht
Atypical methylation of the interleukin-8 gene correlates strongly with the metastatic potential of breast carcinoma cells
PNAS, November 25, 2003; 100(24): 13988 - 13993.
[Abstract] [Full Text] [PDF]




HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Cancer Research Clinical Cancer Research
Cancer Epidemiology Biomarkers & Prevention Molecular Cancer Therapeutics
Molecular Cancer Research Cancer Prevention Research
Cancer Prevention Journals Portal Cancer Reviews Online
Annual Meeting Education Book Meeting Abstracts Online
Copyright © 2001 by the American Association for Cancer Research.